Sudden cardiac death post arrest care and prevention

WikiDoc Resources for Sudden cardiac death post arrest care and prevention
Articles
Most recent articles on Sudden cardiac death post arrest care and prevention Most cited articles on Sudden cardiac death post arrest care and prevention Review articles on Sudden cardiac death post arrest care and prevention Articles on Sudden cardiac death post arrest care and prevention in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sudden cardiac death post arrest care and prevention Images of Sudden cardiac death post arrest care and prevention Photos of Sudden cardiac death post arrest care and prevention Podcasts & MP3s on Sudden cardiac death post arrest care and prevention Videos on Sudden cardiac death post arrest care and prevention
Evidence Based Medicine
Cochrane Collaboration on Sudden cardiac death post arrest care and prevention Bandolier on Sudden cardiac death post arrest care and prevention TRIP on Sudden cardiac death post arrest care and prevention
Clinical Trials
Ongoing Trials on Sudden cardiac death post arrest care and prevention at Clinical Trials.gov Trial results on Sudden cardiac death post arrest care and prevention Clinical Trials on Sudden cardiac death post arrest care and prevention at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sudden cardiac death post arrest care and prevention NICE Guidance on Sudden cardiac death post arrest care and prevention NHS PRODIGY Guidance FDA on Sudden cardiac death post arrest care and prevention CDC on Sudden cardiac death post arrest care and prevention
Books
Books on Sudden cardiac death post arrest care and prevention
News
Sudden cardiac death post arrest care and prevention in the news Be alerted to news on Sudden cardiac death post arrest care and prevention News trends on Sudden cardiac death post arrest care and prevention
Commentary
Blogs on Sudden cardiac death post arrest care and prevention
Definitions
Definitions of Sudden cardiac death post arrest care and prevention
Patient Resources / Community
Patient resources on Sudden cardiac death post arrest care and prevention Discussion groups on Sudden cardiac death post arrest care and prevention Patient Handouts on Sudden cardiac death post arrest care and prevention Directions to Hospitals Treating Sudden cardiac death post arrest care and prevention Risk calculators and risk factors for Sudden cardiac death post arrest care and prevention
Healthcare Provider Resources
Symptoms of Sudden cardiac death post arrest care and prevention Causes & Risk Factors for Sudden cardiac death post arrest care and prevention Diagnostic studies for Sudden cardiac death post arrest care and prevention Treatment of Sudden cardiac death post arrest care and prevention
Continuing Medical Education (CME)
CME Programs on Sudden cardiac death post arrest care and prevention
International
Sudden cardiac death post arrest care and prevention en Espanol Sudden cardiac death post arrest care and prevention en Francais
Business
Sudden cardiac death post arrest care and prevention in the Marketplace Patents on Sudden cardiac death post arrest care and prevention
Experimental / Informatics
List of terms related to Sudden cardiac death post arrest care and prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Timing of Sudden Cardiac Death Following ST elevation MI

Patients with STEMI are at risk of sudden cardiac death. The timing of sudden cardiac death following STEMI is as follows:

• In the first 3 months after STEMI one quarter of sudden cardiac deaths occur. This statistic is critical in so far as implantable cardiac defibrillators are often not implanted in the first three months. It is for this reason that wearable defibrillators are sometimes used in patients with a large MI and reduced ejection fraction.

• In the first year following STEMI one half of the sudden cardiac deaths occur.

• Beyond one year, there is still an increased risk of sudden cardiac death for a prolonged period of time.

Medical Therapy to Prevent Sudden Death Following STEMI

Therapies aimed to reduce disease progression, stabilize plaque, improve left ventricular function, and reduce ischemia may minimize the risk of sudden cardiac death. These therapies include beta blockade, ACE inhibition, and statins.

Beta Blockers

Beta blocker administration has been associated with a reduction in sudden cardiac death from 5.0% to 3.3% in a review of 13 trials . The reduction in SCD was greatest among patients with congestive heart failure. Among patients with an ICD, beta blocker administration has been associated with an additional reduction in mortality in MADIT II (hazard ratio of 0.42 to 0.44) and a lower frequency of ICD discharge (hazard ratio of 0.48) .

ACE inhibition

ACE inhibitor administration has been associated with a 20% relative and a 1.4% absolute reduction in the risk of SCD in a metanalysis of randomized trials .

Angiotensin II receptor blockers (ARBs)

If a patient is intolerant to ACE inhibitor, an ARB can be administered. Valsartan is non-inferior to captopril in reducing post MI mortality, and may therefore confer similar benefits in SCD .

Statin Therapy

Among patients with an ICD implanted, statin administration has been associated with a reduction in documented arrhythmias post-MI in observation studies .

Aldosterone antagonists

In the EPHESUS trial, among the specific subgroup of post MI patients who have left ventricular dysfunction and / or diabetes, eplerenone administration was associated with reduction in all cause and SCD mortality (4.9% vs 6.1%).

Prevention of Sudden Death and Implantable Cardioverter Defibrillators Following STEMI

• The majority, but not all trials indicate that there is a benefit to placement of an ICD after the first three months of survival following STEMI in patients with a reduced LVEF at 3 months.
• The DINAMIT and IRIS trials did not show a benefit of ICD placement during the first 3 months after STEMI.
• Likewise, it should be noted that MADITT II excluded patients who had an MI or revascularization within the preceding 40 days.
• Amiodarone was associated with a reduction in arrhythmic death among patients with an LVEF of <40% following STEMI, but all cause mortality was not imprlved in the CAMIAT trial.
• An external cardiac defibrillator vest can be prescribed in high risk patients with a low ejection fraction while the patient is awaiting assessment of their LVEF at 3 months.

Wearable Defibrillators

In patients with a large MI with a low EF who are awaiting permanent ICD implantation, use of a wearable defibrillator is a reasonable strategy.

ACC / AHA Guidelines- Recommendations for Implantable Cardioverter Defibrillators (DO NOT EDIT)

“

Class I 1. ICD therapy is indicated in patients who are survivors of cardiac arrest due to VF or hemodynamically unstable sustained VT after evaluation to define the cause of the event and to exclude any completely reversible causes. (Level of Evidence: A) 2. ICD therapy is indicated in patients with structural heart disease and spontaneous sustained VT, whether hemodynamically stable or unstable. (Level of Evidence: B) 3. ICD therapy is indicated in patients with syncope of undetermined origin with clinically relevant, hemodynamically significant sustained VT or VF induced at electrophysiological study. (Level of Evidence: B) 4. ICD therapy is indicated in patients with LVEF less than 35% due to prior MI who are at least 40 days post-MI and are in NYHA functional Class II or III. (Level of Evidence: A) 5. ICD therapy is indicated in patients with nonischemic DCM who have an LVEF less than or equal to 35% and who are in NYHA functional Class II or III. (Level of Evidence: B) 6. ICD therapy is indicated in patients with LV dysfunction due to prior MI who are at least 40 days post-MI, have an LVEF less than 30%, and are in NYHA functional Class I. (Level of Evidence: A) 7. ICD therapy is indicated in patients with nonsustained VT due to prior MI, LVEF less than 40%, and inducible VF or sustained VT at electrophysiological study. (Level of Evidence: B) Class IIa 1. ICD implantation is reasonable for patients with unexplained syncope, significant LV dysfunction, and nonischemic DCM. (Level of Evidence: C) 2. ICD implantation is reasonable for patients with sustained VT and normal or near-normal ventricular function. (Level of Evidence: C) 3. ICD implantation is reasonable for patients with HCM who have 1 or more major{dagger} risk factors for SCD. (Level of Evidence: C) 4. ICD implantation is reasonable for the prevention of SCD in patients with ARVD/C who have 1 or more risk factors for SCD. (Level of Evidence: C) 5. ICD implantation is reasonable to reduce SCD in patients with long-QT syndrome who are experiencing syncope and/or VT while receiving beta blockers. (Level of Evidence: B) 6. ICD implantation is reasonable for non hospitalized patients awaiting transplantation. (Level of Evidence: C) 7. ICD implantation is reasonable for patients with Brugada syndrome who have had syncope. (Level of Evidence: C) 8. ICD implantation is reasonable for patients with Brugada syndrome who have documented VT that has not resulted in cardiac arrest. (Level of Evidence: C) 9. ICD implantation is reasonable for patients with catecholaminergic polymorphic VT who have syncope and/or documented sustained VT while receiving beta blockers. (Level of Evidence: C) 10. ICD implantation is reasonable for patients with cardiac sarcoidosis, giant cell myocarditis, or Chagas disease. (Level of Evidence: C) Class IIb 1. ICD therapy may be considered in patients with nonischemic heart disease who have an LVEF of less than or equal to 35% and who are in NYHA functional Class I. (Level of Evidence: C) 2. ICD therapy may be considered for patients with long-QT syndrome and risk factors for SCD. (Level of Evidence: B) 3. ICD therapy may be considered in patients with syncope and advanced structural heart disease in whom thorough invasive and noninvasive investigations have failed to define a cause. (Level of Evidence: C) 4. ICD therapy may be considered in patients with a familial cardiomyopathy associated with sudden death. (Level of Evidence: C) 5. ICD therapy may be considered in patients with LV noncompaction. (Level of Evidence: C) Class III 1. ICD therapy is not indicated for patients who do not have a reasonable expectation of survival with an acceptable functional status for at least 1 year, even if they meet ICD implantation criteria specified in the Class I, IIa, and IIb recommendations above. (Level of Evidence: C) 2. ICD therapy is not indicated for patients with incessant VT or VF. (Level of Evidence: C) 3. ICD therapy is not indicated in patients with significant psychiatric illnesses that may be aggravated by device implantation or that may preclude systematic follow-up. (Level of Evidence: C) 4. ICD therapy is not indicated for NYHA Class IV patients with drug-refractory congestive heart failure who are not candidates for cardiac transplantation or CRT-D. (Level of Evidence: C) 5. ICD therapy is not indicated for syncope of undetermined cause in a patient without inducible ventricular tachyarrhythmias and without structural heart disease. (Level of Evidence: C) 6. ICD therapy is not indicated when VF or VT is amenable to surgical or catheter ablation (e.g., atrial arrhythmias associated with the Wolff-Parkinson-White syndrome, RV or LV outflow tract VT, idiopathic VT, or fascicular VT in the absence of structural heart disease). (Level of Evidence: C) 7. ICD therapy is not indicated for patients with ventricular tachyarrhythmias due to a completely reversible disorder in the absence of structural heart disease (e.g., electrolyte imbalance, drugs, or trauma). (Level of Evidence: B)

”

ACC / AHA Guidelines- Recommendations for Implantable Cardioverter-Defibrillators in Pediatric Patients and Patients With Congenital Heart Disease (DO NOT EDIT)

“

Class I 1. ICD implantation is indicated in the survivor of cardiac arrest after evaluation to define the cause of the event and to exclude any reversible causes. (Level of Evidence: B) 2. ICD implantation is indicated for patients with symptomatic sustained VT in association with congenital heart disease who have undergone hemodynamic and electrophysiological evaluation. Catheter ablation or surgical repair may offer possible alternatives in carefully selected patients. (Level of Evidence: C) Class IIa 1. ICD implantation is reasonable for patients with congenital heart disease with recurrent syncope of undetermined origin in the presence of either ventricular dysfunction or inducible ventricular arrhythmias at electrophysiological study. (Level of Evidence: B) Class IIb 1. ICD implantation may be considered for patients with recurrent syncope associated with complex congenital heart disease and advanced systemic ventricular dysfunction when thorough invasive and noninvasive investigations have failed to define a cause. (Level of Evidence: C) Class III 1. All Class III recommendations found in Section 3, "Indications for Implantable Cardioverter-Defibrillator Therapy," apply to pediatric patients and patients with congenital heart disease, and ICD implantation is not indicated in these patient populations. (Level of Evidence: C)

”

Unresolved Questions in Identifying the Optimal Patients for ICD Implanatation Following STEMI

The benefits of ICD placement in those patients over the age of 75 and in those with impaired renal function is not well defined, but post-hoc analyses from randomized trials suggest a lack of benefit in these populations.